Biohaven’s Non-Migraine Portfolio Takes Another Hit As Verdiperstat Fails In ALS

Pfizer is buying Biohaven's migraine portfolio, but the rest of the pipeline is poised to be spun out and there have been two development setbacks. Despite verdiperstat's failure in ALS, the field had a same-day win with Amylyx's Relyvrio approval.

While it came as a disappointment, the failure of Biohaven Pharmaceutical Holding Company Ltd.’s verdiperstat in amyotrophic lateral sclerosis (ALS) was not a big surprise, and it won't impact the planned sale of Biohaven to Pfizer Inc. since the deal was tied to the migraine drug portfolio.

Biohaven's non-migraine pipeline is poised to be spun out into a new company, and the developments on that front have not been encouraging. Biohaven has experienced two clinical trial failures outside of the migraine space since Pfizer’s $11.6bn acquisition of Biohaven was announced in May

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

In Brief: US FDA Delay Sends Biohaven Shares Down

16 May 2025

• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

Multiple Launches Help Lilly’s Japan Growth

15 May 2025

• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Lundbeck Lifted By Leap In Migraine Therapy Sales

14 May 2025

• By Kevin Grogan

Vyepti revenues rise by nearly 70% in the first quarter.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

13 May 2025

• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

19 May 2025

• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.